A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis

Muscle involvement in AL amyloidosis is a rare condition, and the diagnosis of amyloid myopathy is often delayed and underdiagnosed. Amyloid myopathy may be the initial manifestation and may precede the diagnosis of systemic AL amyloidosis. Here, we report the case of a 73-year-old man who was referred to our center for a monoclonal gammopathy of undetermined significance (MGUS) diagnosed since 1999. He reported a progressive weakness of proximal muscles of the legs with onset six months previously. Muscle biopsy showed mild histopathology featuring alterations of nonspecific type with a mixed myopathic and neurogenic involvement, and the diagnostic turning point was the demonstration of characteristic green birefringence under cross-polarized light following Congo red staining of perimysial vessels. Transmission electron microscopy (TEM) confirmed amyloid fibrils around perimysial vessels associated with collagen fibrils. A stepwise approach to diagnosis and staging of this disorder is critical and involves confirmation of amyloid deposition, identification of the fibril type, assessment of underlying amyloidogenic disorder, and evaluation of the extent and severity of amyloidotic organ involvement.

[1]  M. Milone,et al.  Characterization of isolated amyloid myopathy , 2017, European journal of neurology.

[2]  D. Dingli,et al.  Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. , 2016, Mayo Clinic proceedings.

[3]  R. Walters,et al.  Muscle diseases: mimics and chameleons , 2014, Practical Neurology.

[4]  G. Merlini,et al.  Systemic light chain amyloidosis: an update for treating physicians. , 2013, Blood.

[5]  M. Dimopoulos,et al.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.

[6]  A. Mammen,et al.  Expanding the spectrum of monoclonal light chain deposition disease in muscle , 2012, Muscle & nerve.

[7]  U. Hellman,et al.  Germ Line Origin and Somatic Mutations Determine the Target Tissues in Systemic AL-Amyloidosis , 2007, PloS one.

[8]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[9]  M. Kornfeld,et al.  Amyloid myopathy: Characteristic features of a still underdiagnosed disease , 2005, Muscle & nerve.

[10]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[12]  A. Engel,et al.  Amyloid myopathy: An underdiagnosed entity , 1998, Annals of neurology.

[13]  W. Brown,et al.  Myopathy in Primary Systemic Amyloidosis , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[14]  M. Fardeau,et al.  In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy. , 1986, The Journal of clinical investigation.

[15]  G. Merlini,et al.  Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium , 2015, Advances in Therapy.